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Cisplatin (cis-diamminedichloroplatinum(II)) and its analogs are known to form
1,2-intrastrand cross-links with guanine bases that lead to DNA distortion and are
responsible for cytotoxicity. Reaction with proteins, especially at methionine residues,
could also be responsible for cytotoxicity (Sandlin, R. D. et al. 2010). A new tridentate
platinum(II) complex with a piperazine ring was successfully designed and synthesized.
In this complex, the platinum is coordinating to all three nitrogens of (1,2dimethylaminoethylpiperazine), which makes it a Platinum triamine compound. A series
of chemical reactions of this compound with guanosine 5’-monophosphate (5’-GMP) and
N-acetylmethionine (N-AcMet) were conducted under different conditions. Reactions
with 5’-GMP show spectra suggesting that the triamine ligand is partially displaced as a
second 5’-GMP residue coordinates. We are hoping that this newly synthesized
compound may have anticancer properties, due the bulky structure of its nitrogen ligand.
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INTRODUCTION
Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy
of human neoplasm (an abnormal growth of cells in the body). Their clinical success is
limited due to intrinsic or acquired resistance to the drug and severe side effects (Dilruba
et Kalayda, 2016). Continuous experimentations with new platinum-based anticancer
drugs are still being conducted.
Platinum complexes represent an important class of drugs, which are used in first-line
therapies of several kinds of tumoral diseases. However, these therapies are not without
obstacles. Intolerable side effects such as nephrotoxicity, neurotoxicity, and myelosuppression and development of resistance limits their therapeutic value (Kapp et al.
2010). According to the binding mode with DNA, platinum(II) compounds are divided
into two classes: bifunctional and monofunctional (Wang et al. 2016). Bifunctional
platinum(II) complexes, such as cisplatin, exert antitumor activities through intrastrand
and/or interstrand linkages with DNA. Platinum(II) complexes bearing only one labile
ligand and forming one bond to the DNA nucleobase are defined as monofunctional
complexes, some of which show significant cellular response different from the classic
bifunctional platinum-based drugs (Wang et al. 2016).
Cisplatin (cis-diamminedichloroplatinum(II)) and its analogs are known to form 1,2intrastrand cross-links with Guanine that leads to DNA distortion and are responsible for
cytotoxicity (Reedijk et al. 1999). The distortion in the DNA double helix or DNA lesion,
which is assumed to largely account for cisplatin cytotoxicity, leads to the initiation of
apoptosis or cell death (Dilruba and Kalayda, 2016). Reaction with proteins, especially at
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methionine residues, may also be responsible for cytotoxicity, but could also be involved
in uptake, resistance, or detoxification pathways (Kartalou et al. 2001). HMG proteins are
mainly involved in gene regulation and chromatin structure. HMG1 and HMG2 recognize
intrastrand DNA adducts between adjacent guanines changing cell cycle events and
subsequently inducing apoptosis. HMG proteins also contribute to cisplatin cytotoxicity
by shielding platinum-DNA adducts from repair (Dilruba and Kalayda, 2016).
One of the great success stories in the field of cancer chemotherapy is the use of
cisplatin; a curative treatment for testicular tumors. Approved by the Food and Drug
Administration in 1978, cisplatin is also administered for several other forms of cancer,
including ovarian, cervical, head and neck, esophageal, and non-small-cell lung cancers.
Only in testicular cancer does the drug reach greater than 90% cure rates, while
approaching 100% in early stage cases (Todd et al. 2009). Treatment can be limited by
toxic side effects, including nephrotoxicity, emetogenesis, and neurotoxicity. Resistance
to cisplatin, either acquired or inherent, is also common. Two other members of the
platinum antitumor drug family, carboplatin and oxaliplatin (Fig. 1), have subsequently
been approved for use in the United States. Whereas carboplatin and cisplatin are crossresistant, oxaliplatin has a different spectrum of activity and has become a first-line
therapy for colorectal cancer (Todd et al. 2009). Platinum-based drugs cisplatin,
carboplatin and oxaliplatin are widely used in the therapy of human neoplasms. However,
their clinical success is limited (Dilruba, S. et al. 2016).
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Figure 1: Chemical structure of Cisplatin, Carboplatin and Oxaliplatin

Mechanism of action of cisplatin:
The mechanism by which the classical platinum drugs elicit an anticancer effect has been
studied for decades (Johnstone et al. 2016). The amine ligands on these drugs can be
chelating or non-chelating and are referred to as the “non-leaving group ligands” because
they remain bound to the metal center throughout the course of intracellular
transformations. In contrast, the “leaving group” ligand(s), which can be mono-dentate
anionic or chelating di-anionic fragments, leave the platinum(II) coordination sphere. The
generalized mechanism of action involves four key steps (Figure 2): (i) cellular uptake,
(ii) aquation/activation, (iii) DNA binding, and (iv) cellular processing of DNA lesions
leading to cell death (Johnstone et al. 2016).
3

The Next Generation of Platinum Drugs, 2016

Figure 2: Steps of mechanism of Cisplatin

The binding of platinum to N7 position of guanine is favored both kinetically and
thermodynamically. Hydrogen-bonding and molecular orbital interactions favor the
binding with the N7 position of guanine, and the rate of platination also depends on the
sequence types and chain length of DNA (Ahmad, 2017).
The two pathways by which cisplatin is most likely taken up by cells are passive
4

diffusion through the plasma membrane and active transport mediated by membrane
proteins. The small size and planar geometry of cisplatin have long been cited as
supportive of passive diffusion. Furthermore, structural analogs of cisplatin do not inhibit
uptake of the drug. Conversely, other studies suggest that active transport is the
predominant mechanism of uptake. For instance, cisplatin uptake has been linked to
expression levels of copper transporters (CTR). Copper transporter 1 (CTR1) is a
transmembrane protein involved in copper homeostasis and was found to play an
important role in the uptake of cisplatin (Dilruba and Kalayda, 2016). Downregulation of
CTR1 is often observed in cisplatin-resistant cells. Also, reactive aldehydes can inhibit
cisplatin uptake, presumably by reacting with membrane proteins that internalize
cisplatin (Johnstone et al. 2016).
Ahmad et al. states that the binding of cisplatin to DNA is irreversible and is therefore
a kinetically rather than thermodynamically controlled process. The reactions of cisplatin
with thiols such as GSH and other proteins affect the amount of cisplatin that is available
for binding to DNA. In the presence of glutathione, the monofunctional Pt–DNA adduct
reacts rapidly with glutathione forming sulfur-bound species that are trapped and can
close to form bifunctional lesions (2017).
Numerous platinum-based compounds have been developed and tested in animals and
humans during the past three decades in an effort to minimize toxic side effects and
acquired drug resistance (Gao et al. 2009). Cisplatin’s mechanism of action has been
accepted as covalent binding to DNA, ultimately resulting in cell death. Using atomic
absorption spectroscopy, Gao et al. have found that at least a few percent of total cellular
accumulated platinum ions are bound to DNA (2009).
5

Cell lines selected for resistance to cisplatin after prolonged culture in the presence of
cisplatin have significantly higher levels of repair than the corresponding parental cell
lines (Parker et al. 1991), indicating that DNA repair is an important determinant of
cisplatin resistance. Kartalou and Essigmann state that Nucleotide excision repair is the
main process by which cisplatin adducts are removed from DNA (2001).
When the Pt(II) complexes reach the DNA, different possibilities for coordination
exist. Binding to DNA primarily occurs through the N7 atom of guanine, while the
binding to N7 and N1 of adenine, and N3 of cytosine occur to a lesser degree (Lippert,
1999). Since DNA contains different sequences of purine and pyrimidine bases, it was
found that 60% of all DNA adducts are represented by intrastrand 1,2-(GpG) cross-links
and about 25% are represented by coordination of the type 1,2-(ApG). Other coordination
modes, for example interstrand cross-links or monofunctional DNA-binding, are less
frequent. Takahara concludes that the intrastrand 1,2-d(GpG) cross-linking induces a
significant distortion in the DNA double helix (1995). This DNA lesion largely accounts
for cisplatin cytotoxicity; and is recognized by several cellular proteins leading to the
repair, replication bypass or intitiation of apoptosois. Dilruba and Kalayda states that
several protein families are involved in the recognition of Pt-DNA adducts including nonhistone chromosomal group proteins 1 and 2 (HMG1 and HMG2), nucleotide excision
repair (NER) proteins and mismatch repair (MMR) proteins (2016). Figure below shows
the different possibilities of coordination of cisplatin to DNA (JaKupec et al. 2003).
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Figure 3: The different possibilities of coordination of cisplatin to DNA

Reactions of platinum(II) triamine complexes with N-acetylmethionine (N-AcMet)
and guanosine 5’-monophosphate (5’-GMP) have been studied for many years;
[Pt(dien)Cl]+ has been shown to react faster with thioethers such as methionine than with
5’-GMP (Williams et al. 2017). The sterically hindered [Pt(Me5dien)(H2O)]2+ complex
(Me5dien= N,N,N’,N’,N”-pentamethyldiethylenetriamine) was the first platinum(II)
triamine complex with a significant kinetic preference for 5’-GMP over N-AcMet
(Sandlin et al. 2010). [Pt(Me5dien)(H2O)]2+ complex slowed reaction with N-AcMet
more than with 5’-GMP so that the latter was kinetically favored. Because the 5’-GMP
ligand is planar at the site of Pt reaction (N7) and the N-AcMet ligand is not planar, the
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steric hindrance affected the reaction with N-AcMet more than 5’-GMP (Williams et al.
2017). Reactions with 5’-GMP represents the major site of reaction of cisplatin with
DNA, whereas methionine is a primary target of reactions with proteins. It is conceivable
that sufficiently bulky platinum complexes would show increased selectivity for reactions
with DNA relative to proteins. Furthermore, it is possible that platinum complexes, with
bulky amine ligands, would tend to react with proteins at residues other than methionine
(Sandlin et al. 2010). Figures below represent the chemical structure of 5’-guanosine
monophosphate and N-acetylmethionine respectively.

Figure 4: Chemical structure of guanosine 5’-monophosphate
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Figure 5: Chemical structure of N-acetylmethionine

Sandlin et al. state that competing S-ligands could affect the efficiency of the drug,
since the anticancer activity of cisplatin is due to a Pt-DNA crosslink (2012).
Intermolecular studies revealed that platinum reaction with methionine and S-ligands is
kinetically favored, but the reaction of platinum with guanine is thermodynamically
favored (Reedijk, 1999). Model studies using 5′- guanosine monophosphate (5′-GMP)
and N-acetylmethionine (N-AcMet) as small molecule models for nucleic acid and
protein residues, respectively, showed a high kinetic preference for sulfur over nitrogen
(S/N) binding (Strukl et al. 2008). Pt–S bond formation is rapid for reactions of platinum
with nucleopeptides such as S-guanosyl-l-homocysteine. Methionine binding may further
stabilize monofunctional Pt- DNA models producing species similar to the mixed
nucleobase/ amino acid compounds. With respect to protein binding, other factors besides
9

donor affinity such as accessibility of binding sites must be considered (Strukl et al.
2008).
Further studies have found that within 1 day of administering cisplatin intravenously,
65-98% of the drug is bound to proteins. It is therefore crucial to better understand the
interaction of platinum complexes with DNA and proteins and to determine what factors
affect the reactions with each (Sandlin et al. 2012).
To further understand the impact of inter/intra-strand DNA cross-linkage on
anticancer activity, chirality and steric factors that can influence DNA binding, different
platinum(II) complexes were synthesized and investigated (Deo et al. 2018). Bulky
ligands protect the platinum center from deactivation in a biological milieu by nonnucleoside nucleophiles such as glutathione or cysteine. The added lipophilicity of such
ligands can also aid in passage through the lipid bilayer of the cell membranes. The
choice of a bidentate or tridentate N -donor ligand adds stability to cationic platinum
complexes and decreases the possibility of undesired substitution reactions at the chelate
(Lovejoy and Lippard, 2009).
The choice of leaving group also plays a role in the biological and antitumor
properties of cationic platinum(II) anticancer drugs. The lability of the Pt–X bond is
crucial for delivery of platinum to DNA without prior deactivation by other biological
nucleophiles. An extremely labile bond will most likely lead either to deactivation before
arrival at the tumor site or toxicity owing to accumulation of platinum in healthy tissue.
An inert leaving group will reduce the level of DNA-bound platinum, with a high
proportion of the compound passing through the body intact. Chloride, the preferred
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leaving group in the original formulation of platinum anticancer drug, is also useful as a
leaving group in the cationic class of compounds. Use of iodide as the leaving group is
expected to depart slowly from the platinum coordination sphere and lead to a more
sluggish DNA modification (Lovejoy and Lippard, 2009).
Wang and Lippard state that novel platinum anticancer drug candidates might be
designed and evaluated so that the platinum atom carries into the tumor cell not only the
DNA- binding warhead, but also a molecular fragment that can interfere with a specific
cellular pathway (2005). Some alternative approaches have led to the discovery of some
promising compounds that are currently in clinical trials; Cis-Ammine (2methylpyridine) dichloroplatinum(II) (ZD0473) was designed to hinder sterically the
approach of glutathione and other cellular thiols that intercept and sequester platinum
drugs before they can reach the genome. ZD0473 resulted in improvement in vitro
activity compared with cisplatin (Wang and Lippard, 2005).
Since toxic side effects and resistance to drugs are factors leading to the lack of
clinical success. The rational design of new platinum(II) compounds that target only
tumor tissue and limits the intrinsic cell resistance to the treatment is the key for clinical
success against cancer cell (Dilruba, 2016). Furthermore, structural modification of
monofunctional platinum(II) complexes, with bulky steric groups, gives rise to greater
efficacy than cisplatin and oxaliplatin in established human cancer cell lines (Wang et al.
2016).
A group of platinum(II)-based DNA intercalators of the type [Pt(IL)(AL)]2+ (where IL is
an intercalating ligand and AL is an ancillary ligand) has demonstrated significant
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potential against human cell lines in vitro, including those that show resistance to current
chemotherapeutic agents. The type and chirality of the ancillary ligand, along with
functional group substitution on the intercalating ligand of platinum compounds, plays an
important role in cytotoxic activity. An interesting structural feature of these new
cytotoxic platinum complexes is the absence of anionic ligands (e.g., chloride) that serve
as leaving groups in traditional platinum antitumor agents. Thus, it would not appear that
covalent binding between the platinum complex and DNA is responsible for their potent
cytotoxicity (Krause-Heuer et al. 2009). As the heterocyclic ligands in a series of
platinum compounds increased in size, the cytotoxicity increased as well (S. Wu et al.
2014). Other monofunctional compounds with steric hindrance have also shown
significant antitumor activity.
Many molecular biological methods have been applied to find targeted biomolecules
in cytotoxic platinum complexes. The ultimate goal was to increase the body of
knowledge about platinum compounds’ role in gene expression with respect to increasing
their utility as anticancer agents. Numerous platinum compounds have been investigated,
and they have displayed significant levels of in vitro antitumoral activity against several
human cancer cell lines (Krause Heuer et al. 2009). To directly compare phenanthriplatin
with conventional Pt- based drugs in vitro, a panel of seven human cancer cell lines of
different origin was treated with cisplatin, oxaliplatin, pyriplatin, or phenanthriplatin for
72 h, and cell viability was evaluated by the MTT assay (a colorimetric assay for
assessing cell metabolic activity). The cytotoxicity of phenanthriplatin is substantially
greater (4–40 times) than that of cisplatin or oxaliplatin. The ultimate objective in cancer
therapy is to find an anticancer drug that kills cancer cells selectively over healthy cells
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by reducing the toxic side effects normally associated with chemotherapy. Normal lung
fibroblasts (MRC5) and cancerous lung (A549) cells were used to evaluate the selectivity
of phenanthriplatin for cancer vs. healthy cells. The A549 and MRC5 cell cultures were
treated with cisplatin or phenanthriplatin for 72 h, after which cell viability was evaluated
by the MTT assay. The ratio of IC50 values in healthy MRC5 cells to those in cancerous
A549 cells was 0.9 for cisplatin compared with 3.9 for phenanthriplatin. The higher ratio
obtained for phenanthriplatin reveals its selectivity for cancer cells, at least in the cellular
monolayer assays used in this study (Park et al. 2012). By connecting theoretical
calculations, biochemistry, chemistry and cellular biology, and the formation of the
structure–activity relationship, Pt(II) complexes will result in a more tailored drug design.
Numerous available data imply that interactions of Pt(II) complexes and the investigation
of the mechanism of their reaction with DNA fragments are important for the anti-tumour
activity of Pt(II) complexes (Bugarcic et al. 2012).
By determining correlations between the spectral parameters, chemical shift and spinspin coupling, NMR spectroscopy lead to the structure determinations of unknown
samples (Gunther, 2013). The physical foundation of NMR spectroscopy lies in the
magnetic properties of atomic nuclei. The interaction of the nuclear magnetic moment
with an external magnetic field, B0, leads to a nuclear energy level diagram. Gunther
states that through a radiofrequency (RF) transmitter, transitions between stationary states
of an element can be stimulated. The absorption of energy is then detected in an RF
receiver and recorded as a spectral line, the so-called resonance signal (2013).
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MATERIALS AND METHODS
Chemicals for NMR studies
Deuterium oxide (D2O) 99.9 atom % D
Potassium tetrachloroplatinate
1,2- dimethylaminoethylpiperazine
Hydrochloric acid (HCl) concentrated.
Synthesis of Platinum Compound
In a flask, we mixed 1000 mg of potassium tetrachloroplatinate, 30 ml water, 1 g of 1,2dimethylaminoethylpiperazine, 9 ml of hydrochloric acid HCl concentrated (the acid will
be added until the pH of the solution reach 2.8). The reaction stirred under heat and
refluxed for 1 hour and 30 minutes, then heat was turned off and the stirrer was left on
overnight. Regular filtration was used to collect the first gray precipitate. We evaporated
the solvent until few particles of yellow precipitate appear in the flask. We moved the
flask to the refrigerator at 4 degree Celsius allowing more time for precipitation to occur.
We washed the product several times by using different solvents such as ethanol, acetone
and DI water. After evaporation of the solvent, a yellow precipitate (our platinum
compound) was collected. By conducting the above reactions, we were able to coordinate
the platinum with all three nitrogens of (1,2-dimethylaminoethylpiperazine) and
synthesize 369.6 mg of pure platinum triamine compound. This compound has a
molecular weight (MW) of 419.05g/mol.
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The process of synthesis leads to the appearance of two dry chemical compounds; gray
and yellow precipitates. Advanced NMR such as HMQC, COSY and 1H NMR spectra
have been collected to identify the platinum triamine compound that will be beneficial to
our research. There were no identifiable peaks from the gray precipitate, and since none
of the starting material was gray, this precipitate could be a side product. The yellow
precipitate is the actual platinum triamine compound that we will be investigating its
chemical reactions with guanosine 5’-monophosphate and N-acetylmethionine. We
changed concentration of the reactants, temperature of the reaction and its pH in order to
understand how our platinum compound reacts with 5’-GMP and N-AcMet. Samples
were prepared with Deuterium oxide (D2O) and checked continuously on 1H NMR.

NMR SPECTROSCOPY

1

H NMR spectra were recorded at 21.0 °C, the analysis of each sample was performed

using D2O as an internal lock. Spectra were acquired under an automation procedure
(shimming and automatic sample loading) requiring about 30 minutes per sample.
Nuclear Magnetic Resonance (NMR) spectra were obtained on a JEOL ECA-500 MHz.
Major products were identified by peak assignment of 1H NMR spectra using
comparisons with 1H NMR spectra from pure compounds and with published data
(Tardieu et al. 2010). As many peaks overlapped in the platinum triamine compound
region (between 2.9 and 4 ppm), (2.0 and 2.6 ppm) for Pt-NAcMet products and (8.2 and
9 ppm) for Pt-GMP products, identification of major products was performed. 195Pt NMR
spectroscopy signal shifts are sensitive parameters that have often been used to identify
15

the number, type, and geometrical arrangement of coordinated ligands (Saad et al. 2010).
195

Pt NMR spectra were also recorded, by using Deuterium oxide (D2O) as the solvent in

each test sample.

RESULTS
1. Characterization of the platinum compound:
The name & structure of synthesized platinum compound: Chloro {1-[2(dimethylamino)ethyl]piperazine} platinum(II) chloride

Figure 6: Chemical structure of synthesized platinum compound

A sample of 4.2 mg of platinum compound diluted in 1 ml D2O was checked on 1H
NMR. The spectra below show a sharp signal at 2.9 ppm which corresponds to the
synthesized platinum compound. The platinum triamine compound has 2 methyl groups
(-CH3) that should be equivalent which lead to the appearance of a sharp single peak at
16

2.9 ppm that will always appear in the 1H NMR spectra even if we change the pH of the
sample. The other peaks (3.2-3.7 ppm) correspond to other hydrogens in the ligand. The
singlet at 2.9 ppm is a key corresponding peak for Chloro{1-[2(dimethylamino)ethylpiperazine} platinum(II) chloride. Furthermore, 195Pt NMR
spectroscopy reveals a peak at -1962 ppm which reflect that all 3 Nitrogen and 1 Oxygen
are coordinated to platinum, and this peak was from displacement of chloride ion (Cl-) by
D2O.

Figure 7: 1H spectrum of platinum compound + D2O at pH2
showing peaks of hydrogens of platinum triamine compound
and other hydrogens in the ligand.
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Figure 8: 1H spectrum of platinum compound + D2O at pH 2 (2 days)
later))

Figure 9: 1H spectrum of platinum compound + D2O at pH 2 (4 days)
later)
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Figure 10: 195Pt NMR of synthesized platinum
compound

2.

1H

NMR Data of Platinum Compound with 5’-GMP

A sample of 4.2 mg of platinum compound and 4.1 mg of GMP dissolved in D2O, was
checked daily on 1H NMR. Multiple signals in the 8.2-9 ppm region appear in each
spectrum. A mono-product should only have 1-2 signals, so the number of signals we see
is highly suggestive of a partial displacement of one of the nitrogens of the triamine
ligand as a second 5’-GMP residue coordinates to platinum.

19

Products

Figure 11: 1H NMR of platinum compound + 5’-GMP (2 days)

Figure 12: 1H NMR of platinum compound + 5’-GMP (4 days)
20

3.

1H

NMR Data of Platinum compound with N-AcMet

A sample of 4.2 mg Platinum compound and 1.9 mg N-AcMet dissolved in D2O, was
prepared and checked daily on 1H NMR. Peaks at 2.04 and 2.6 ppm correspond to the
products that have platinum coordinated to N-AcMet. Peaks at 2.02 and 2.09 ppm are the
regular peaks for two methyls on N-AcMet. Since a mono-product should only have 1-2
singlets, N-AcMet was able to coordinate to platinum by replacing the chloride ion and
forming only mono-products. There was no signal that proved the displacement of one of
the nitrogen of the platinum compound while interacting with N-AcMet.

Figure 13: 1H NMR of platinum compound + N-AcMet (2 days)
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Figure 14: 1H NMR of platinum compound + N-AcMet (4 days)

4. Competition reactions:
During the first and second synthesis of the same platinum compound, we were having
conflicted results toward which reagent is reacting faster with platinum compound. Many
times, data from 1H NMR supported the idea that 5’-GMP was reacting faster than NAcMet, but unfortunately other 1H NMR spectra disproved the same idea. Since the
NMR was down for a couple of months, no consistent and specific results could be
gathered.
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DISCUSSION
According to Lippard, chloride is defined as the preferred leaving group in the original
formulation of platinum anticancer drug structure-activity relationships (2009).
Furthermore, the stability of platinum(II) compounds with three amines and one leaving
group is not always guaranteed. The possible loss or displacement of an amine by a
biological nucleophile to form a bifunctional, potentially neutral species must be
considered (Lippard and Lovejoy, 2009).
Park et al. state that Phenanthriplatin has significant anticancer activity due in part to the
large phenanthridine ligand attached to the platinum atom (2012). This platinum complex
binds to DNA and blocks transcription, leading to cytotoxicity in a number of cancer cell
lines at lower doses than cisplatin. Studies of phenanthriplatin in the National Cancer
Institute 60-cell tumor panel screen revealed that the cellular uptake of phenanthriplatin is
substantially greater than that of cisplatin because of the hydrophobicity of the
phenanthridine ligand. Phenanthriplatin binds more effectively to 5 -deoxyguanosine
monophosphate than to N-acetyl methionine. This chemistry supports DNA as a viable
cellular target for phenanthriplatin and suggests that it may avoid cytoplasmic platinum
scavengers with sulfur-donor ligands that convey drug resistance (Park et al. 2012).
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Figure 15: Chemical structure of Phenanthriplatin

Since the synthesized platinum compound had specific interactions with 5’-GMP; the
displacement of its nitrogen ligand and the appearance of bis-products highly suggest that
the platinum triamine compound may have some cytotoxicity effect against cancer cell
lines.
In order to understand the effect of steric bulk of the carrier ligand on the bound
guanine derivative, Andrepont et al. conducted a study that revealed the bulk of the 6/6’Me groups in Pt(N(H)6,6’-Me2dpa) weaken the Pt-N bond to such an extent that the
tridentate ligand converted to a bi-dentate ligand (Figure 16). Having one pyridyl chain
dangling, facilitating coordination of 9-EtG, first to a monoadduct and then to a
bisadduct. This chemistry showing the facile opening of chelate rings by nucelobase
addition to Pt(II) compounds is interesting and unusual (Andrepont et al. 2015).
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Furthermore, a mono-functional Pt(II) complex with bulky carrier ligands that are
chelates forming Pt-N bonds of normal length may not necessarily contain Pt-N bonds
strong enough to prevent bi-functional binding to DNA (Andrepont et al. 2015).

Figure 16: Conversion of a Tridentate ligand Pt(N(H)6,6’-Me2dpa)

The synthesized platinum compound Chloro{1-[2-(dimethylamino)ethyl]piperazine}
platinum(II) chloride may have similar displacement of its nitrogen ligand when a second
5’-GMP interacts with platinum (Pt).
Gruner states that when [Pt(Et2dien)Cl]Cl reacted with N-AcMet, the N-AcMet
displaced the chloride ion (2014). When [Pt(Et2dien)Cl]Cl was reacted with 5’-GMP, the
5’-GMP was able to displace the chloride ion.
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Figure 17: Reaction of [Pt(Et2dien)Cl]Cl with N-AcMet

Figure 18: Reaction of [Pt(Et2dien)Cl]Cl with 5’-GMP

When [Pt(Et2dien)Cl]Cl is reacted with N-AcMet and 5’-GMP, the results indicated the
formation of a product that has 5’-GMP and N-AcMet both bound to the central platinum
atom and one nitrogen of the triamine ligand was displaced by the 5’-GMP (Gruner,
2014). The platinum compound [Pt(Et2dien)Cl]Cl shows similar reactions to our
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synthesized platinum compound when it is reacting with N-AcMet and 5’-GMP, but the
difference is that [Pt(Et2dien)Cl]Cl reacts faster with N-AcMet more than with 5’-GMP.
Furthermore [Pt(Et2dien)Cl]Cl produces only mono-product while reacting with 5’-GMP,
but our synthesized platinum compound produces multiple signals in the 8.2-9 ppm
region which reflects the coordination of a second 5’-GMP residue to platinum.

C ONCLUSION
The platinum triamine compound shows specific reactions with Guanosine 5’monophosphate (5’-GMP) and N-Acetylmethionine (N-AcMet). When 5’-GMP binds to
the central platinum atom, the steric strain is so large that leads to a displacement of one
of the nitrogens of triamine ligand. This conformation must be more stable than the
original conformation to cause the nitrogen containing ligand to dissociate from the
central platinum atom. Since phenanthriplatin has significant anticancer activity due in
part to the large phenanthridine ligand attached to the platinum atom, and it also binds
more effectively to 5 -deoxyguanosine monophosphate than to N-acetylmethionine (Park
et al. 2012). The bulky structure of Chloro{1-[2-(dimethylamino)ethyl]piperazine}
platinum(II) chloride complex and its reaction with 5’-GMP and N-AcMet leads us to
believe that this synthesized compound may have anticancer properties, with the large
nitrogen ligand being able to block DNA transcription or replication enzymes.
Further plans have been scheduled to test the cytotoxicity of this compound against
cancer cell line Ntera2 (testicular cancer cell line) in order to understand its mechanism
of action at the cellular level. Chemical and biological properties of platinum-based drugs
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will continue to be investigated to explore the function of bulky amine ligands, in
addition to the mechanism of action. The major challenges that face the
chemists/researchers include the design of new platinum anticancer drugs that are
significantly different in their spectrum of activity from those of cisplatin, oxaliplatin,
and carboplatin. New platinum-based drug combinations and identification of predictive
markers for patient response and side effects are likely to shape future developments in
chemistry.
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